{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:40:55Z","timestamp":1791218455810,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1038\/sj.bjc.6605987","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T21:06:22Z","timestamp":1289941582000},"page":"1783-1787","source":"Crossref","is-referenced-by-count":126,"title":["A Phase 1b\/2 trial of mapatumumab in patients with relapsed\/refractory non-Hodgkin's lymphoma"],"prefix":"10.1038","volume":"103","author":[{"given":"A","family":"Younes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H A","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N L","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"BF6605987_CR1","first-page":"8104","volume":"28","author":"D Belada","year":"2010","unstructured":"Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL (2010) Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). ASCO Meeting Abstracts 28: 8104","journal-title":"ASCO Meeting Abstracts"},{"key":"BF6605987_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244","journal-title":"J Clin Oncol"},{"key":"BF6605987_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1365-2141.2005.05656.x","volume":"130","author":"GV Georgakis","year":"2005","unstructured":"Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130: 501\u2013510","journal-title":"Br J Haematol"},{"key":"BF6605987_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2007.12.011","volume":"61","author":"FA Greco","year":"2008","unstructured":"Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82\u201390","journal-title":"Lung Cancer"},{"key":"BF6605987_CR5","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1158\/1078-0432.CCR-07-1416","volume":"14","author":"SJ Hotte","year":"2008","unstructured":"Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM (2008) A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 14: 3450\u20133455","journal-title":"Clin Cancer Res"},{"key":"BF6605987_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4020-6554-5_7","volume":"615","author":"RC Humphreys","year":"2008","unstructured":"Humphreys RC, Halpern W (2008) Trail receptors: targets for cancer therapy. Adv Exp Med Biol 615: 127\u2013158","journal-title":"Adv Exp Med Biol"},{"key":"BF6605987_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.juro.2007.01.018","volume":"177","author":"X Jin","year":"2007","unstructured":"Jin X, Wu XX, Abdel-Muneem Nouh MA, Kakehi Y (2007) Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol 177: 1894\u20131899","journal-title":"J Urol"},{"key":"BF6605987_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/path.1364","volume":"200","author":"JJ Koornstra","year":"2003","unstructured":"Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S (2003) Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200: 327\u2013335","journal-title":"J Pathol"},{"key":"BF6605987_CR9","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","volume":"13","author":"S Maddipatla","year":"2007","unstructured":"Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13: 4556\u20134564","journal-title":"Clin Cancer Res"},{"key":"BF6605987_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2005-12-007971","volume":"108","author":"E Menoret","year":"2006","unstructured":"Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C (2006) Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108: 1346\u20131352","journal-title":"Blood"},{"key":"BF6605987_CR11","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-09-0996","volume":"15","author":"CH Mom","year":"2009","unstructured":"Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15: 5584\u20135590","journal-title":"Clin Cancer Res"},{"key":"BF6605987_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","volume":"92","author":"L Pukac","year":"2005","unstructured":"Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430\u20131441","journal-title":"Br J Cancer"},{"key":"BF6605987_CR13","doi-asserted-by":"publisher","first-page":"5528s","DOI":"10.1158\/1078-0432.CCR-07-0982","volume":"13","author":"MR Smith","year":"2007","unstructured":"Smith MR, Jin F, Joshi I (2007) Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 13: 5528s\u20135534s","journal-title":"Clin Cancer Res"},{"key":"BF6605987_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1046\/j.1365-2141.1997.4393250.x","volume":"99","author":"V Snell","year":"1997","unstructured":"Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99: 618\u2013624","journal-title":"Br J Haematol"},{"key":"BF6605987_CR15","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1200\/JCO.2006.08.8898","volume":"25","author":"AW Tolcher","year":"2007","unstructured":"Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390\u20131395","journal-title":"J Clin Oncol"},{"key":"BF6605987_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/sj.bjc.6605507","volume":"102","author":"T Trarbach","year":"2010","unstructured":"Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506\u2013512","journal-title":"Br J Cancer"},{"key":"BF6605987_CR17","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood.V98.10.3058","volume":"98","author":"DY Zang","year":"2001","unstructured":"Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ (2001) Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 98: 3058\u20133065","journal-title":"Blood"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605987","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:48:09Z","timestamp":1684414089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["BF6605987"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605987","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}